Wolfe Research Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its target price increased by equities researchers at Wolfe Research from $155.00 to $180.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wolfe Research’s price target suggests a potential upside of 17.00% from the company’s current price.

Several other analysts have also commented on MRK. UBS Group increased their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. The Goldman Sachs Group boosted their target price on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday. Argus upped their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Finally, Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research report on Wednesday, August 12th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $147.60.

Merck & Co., Inc. Stock Up 2.1%

Shares of NYSE MRK traded up $3.19 during trading hours on Tuesday, hitting $153.85. 3,201,016 shares of the stock were exchanged, compared to its average volume of 10,838,494. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $379.57 billion, a PE ratio of 123.46, a PEG ratio of 6.40 and a beta of 0.19. The firm has a fifty day moving average price of $128.81 and a 200-day moving average price of $121.53. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $155.10.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current year.

Insider Activity

In related news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares during the period. Sivia Capital Partners LLC grew its position in shares of Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the period. Diversify Advisory Services LLC increased its stake in shares of Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC raised its holdings in Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Argus raised its price target to $170 and upgraded Merck to “Buy,” up from a $145 target. The new target implies roughly 11% upside from the referenced price and reinforces growing Wall Street confidence in Merck’s outlook. Tickerreport.com article
• Positive Sentiment: Positive Phase 3 results from Merck and Moderna’s INTerpath-001 trial showed that the personalized neoantigen therapy intismeran autogene, used with Merck’s Keytruda, cleared a major hurdle in resected melanoma. The results strengthen expectations for a potentially meaningful expansion of Keytruda’s cancer franchise and helped add billions to Merck’s market value. TheStreet article
• Positive Sentiment: The cancer-vaccine data also improved investor confidence in Moderna’s messenger-RNA platform and related personalized cancer treatments, indirectly highlighting the strategic value of Merck’s collaboration and Keytruda combination. Moderna and Merck Cancer Vaccine Success article
• Neutral Sentiment: Market commentary points to a possible rotation away from technology stocks and toward other sectors. That environment may favor relatively defensive large-cap healthcare companies such as Merck, although the broader market shift is not specific to MRK. Jim Cramer market rotation article
• Neutral Sentiment: Merck’s recent move to annual highs reflects a combination of favorable company catalysts and Wall Street price-target increases, but profit-taking across biotechnology shares and mixed market sentiment could contribute to near-term volatility. Stocktwits article

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.